Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX)
1.5700 x 5 1.7900 x 1
Post-market by (Cboe BZX)
1.6400 +0.0700 (+4.46%) 04/17/25 [NASDAQ]
1.5700 x 5 1.7900 x 1
Post-market 1.6400 unch (unch) 15:15 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.6000
Day High
1.6894
Open 1.6000
Previous Close 1.5700 1.5700
Volume 16,500 16,500
Avg Vol 41,610 41,610
Stochastic %K 64.85% 64.85%
Weighted Alpha -27.58 -27.58
5-Day Change +0.1770 (+12.10%) +0.1770 (+12.10%)
52-Week Range 1.2600 - 2.7100 1.2600 - 2.7100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,464
  • Shares Outstanding, K 27,722
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,610 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.49

Options Overview Details

View History
  • Implied Volatility 313.72% ( -3.27%)
  • Historical Volatility 87.82%
  • IV Percentile 79%
  • IV Rank 37.59%
  • IV High 791.11% on 03/18/25
  • IV Low 26.18% on 07/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 432
  • Open Int (30-Day) 315

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3400 +22.39%
on 04/08/25
Period Open: 1.7300
2.0591 -20.35%
on 03/19/25
-0.0900 (-5.20%)
since 03/17/25
3-Month
1.3400 +22.39%
on 04/08/25
Period Open: 2.0400
2.1399 -23.36%
on 02/10/25
-0.4000 (-19.61%)
since 01/17/25
52-Week
1.2600 +30.16%
on 10/04/24
Period Open: 2.5000
2.7100 -39.48%
on 12/06/24
-0.8600 (-34.40%)
since 04/17/24

Most Recent Stories

More News
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

IMMX : 1.6400 (+4.46%)
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

IMMX : 1.6400 (+4.46%)
Immix Biopharma Reports Promising Initial Clinical Data for NXC-201 in Phase 1b/2 NEXICART-2 Trial for Relapsed/Refractory AL Amyloidosis

Four patients in the NEXICART-2 trial normalized disease markers after NXC-201 treatment, with promising initial responses reported.Quiver AI SummaryImmix Biopharma, Inc. announced positive initial clinical...

IMMX : 1.6400 (+4.46%)
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

IMMX : 1.6400 (+4.46%)
Immix Biopharma Announces Promising Clinical Results for CAR-T Therapy NXC-201 in Treating Relapsed/Refractory AL Amyloidosis

NXC-201 shows promising efficacy and safety in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate.Quiver AI SummaryImmix Biopharma, Inc. announced promising results from the...

IMMX : 1.6400 (+4.46%)
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

IMMX : 1.6400 (+4.46%)
Immix Biopharma Reports 75% Complete Response Rate and 31.5-Month Response Duration for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis at ASH 2024

Immix Biopharma reports 75% complete response rate for CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients at ASH 2024.Quiver AI SummaryImmix Biopharma, Inc. reported promising results from its...

IMMX : 1.6400 (+4.46%)
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

IMMX : 1.6400 (+4.46%)
Immix Biopharma to Host Conference Call on CAR-T NXC-201 Developments for AL Amyloidosis on December 10, 2024

Immix Biopharma will discuss CAR-T NXC-201 developments in AL Amyloidosis on a December 10 conference call.Quiver AI SummaryImmix Biopharma, Inc. will hold a conference call on December 10, 2024, at 4:30...

IMMX : 1.6400 (+4.46%)
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

IMMX : 1.6400 (+4.46%)

Business Summary

Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 1.7757
2nd Resistance Point 1.7325
1st Resistance Point 1.6863
Last Price 1.6400
1st Support Level 1.5969
2nd Support Level 1.5537
3rd Support Level 1.5075

See More

52-Week High 2.7100
Fibonacci 61.8% 2.1561
Fibonacci 50% 1.9850
Fibonacci 38.2% 1.8139
Last Price 1.6400
52-Week Low 1.2600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro